Interleukin-2 Bolus Infusion as Late Consolidation Therapy in 2nd Remission of Acute Myeloblastic Leukemia

References

• McMillan A. K., Goldstone A. H., Linch D. C., Gribben J. G., Patterson K. G., Richards J. D. M., Franklin I., Boughton B. J., Milligan D. W., Leyland M., Hutchison R. M., Newland A. C. High-dose chemotherapy and autologous bone marrow transplantation in acute myelocytic leukemia. Blood 1990; 67: 480–488
   Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. J., Rimm A. A., Ringden O., Rozman C., Speck B., Truirr R. L., Zwaan P. E., Bortin M. M. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Naparsteck E., Or R., Weiss L. The graft versus leukemia (GvL) phenomenon: is GvL separable from GVHD?. Bone Marrow Transplant 1990; 6: 155–161
   PubMed Web of Science ®Google Scholar
• Sullivan K. M., Weiden P. L., Storb R., Withersporn R. P., Fefer A., Fisher L., Buckner C. D., Anasetti C., Appelbaum F. R., Badger C., Beatty P., Bensinger W., Berenson R., Bigelow C., Cheever M. A., Clift R., Deeg H. J., Doney K., Greenberg P., Hansen J. A., Hill R., Loughran T., Martin P., Neimann P. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–1728
   PubMed Web of Science ®Google Scholar
• Hercend T., Takvorian T., Nowill A., Tantravahi R., Moingeon P., Anderson K. C., Murray C., Bohuon C., Ythier A., Ritz J. Characterization of natural killer cells with anti-leukemia activity following allogeneic bone marrow transplantation. Blood 1986; 67: 722–728
   PubMed Web of Science ®Google Scholar
• Reittie J. E., Gottlieb D., Heslop H. E., Leger O., Brexler H. G., Hazlehurst G., Hoffbrand A. V., Brenner M. K. Endogenously generated activated killer cells circulate after autologous and allogeneic bone marrow transplantation but not after chemotherapy. Blood 1989; 73: 1351–1358
   PubMed Web of Science ®Google Scholar
• Jadus M. R., Wepsic H. T. The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 1992; 10: 1–14
   PubMed Web of Science ®Google Scholar
• Foa R., Guarini A., Tos G. A., Cardona S., Fierro G. T., Meloni G., Tosti S., Mandelli F., Gavosto F. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: Evidence of in vivo lymphokine activated killer cell generation. Cancer Res. 1991a; 51: 964–968
   PubMed Web of Science ®Google Scholar
• Tratkiweicz J. A., Szer J., Boyd R. L. Lym-phokineactivated killer cytotoxicity against leukemic blast cells. Clin. Exp. Immunol. 1990; 80: 94–99
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Thomas X., Campos L., Fiere D., Dore J. F. Susceptibility of acute myelogenous blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance. Leuk. Res. 1992; 16: 673–680
   PubMed Web of Science ®Google Scholar
• Jahn B., Bergmann L., Fenchel K., Weidmann E., Schwulera U., Mitrou P. S. CD3+CD4+ T-cells as effective cells of autologous blast specific cytotoxicity in acute myelocytic leukemia. Ann. Haematol. 1992; 65(Suppl.)74, Abstract
   Google Scholar
• Foa R., Meloni G., Tosti S., Novarino A., Fenu S., Gavosto F., Mandelli F. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. Bri. J. Haematol. 1991; 77: 491–496
   PubMed Web of Science ®Google Scholar
• Gottlieb D. J., Brenner M. K., Heslop H. E., Bianchi A. C. M., Bello-Fernandez C., Mehta A. B., Newland A. C., Galazka A. R., Scott E. M., Hoffbrand A. V., Prentice H. G. A phase I clinical trial of recombinant interleukin 2 following high dose chemoradiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br. J. Cancer 1989; 60: 610–615
   PubMed Web of Science ®Google Scholar
• Foa R. Does interleukin-2 have a role in the management of acute leukemia. J. Clin. Oncol. 1993; 11: 1817–1825
   PubMed Web of Science ®Google Scholar
• Hamon M. D., Prentice H. G., Gottlieb J. D., MacDonald I. D., Cunningham J. M., Smith O. P., Gilmore M., Gandhi L., Collis C. Immunotherapy with interleukin-2 after ABMT in AML. Bone Marrow Transplant 1993; 11: 399–401
   PubMed Web of Science ®Google Scholar
• Bol S. J., Rosendorf H. S., Rontelap C. P., Hennen L. A. Cellular cytotoxicity assessed by the Cr51 release assay. J. Immunol. Meth. 1986; 90: 15–23
   PubMed Web of Science ®Google Scholar
• Bergmann L., Fenchel K., Enzinger H. M., Weidmann E., Jahn B., Jonas D., Mitrou P. S. Daily alternating application of high dose interferon-alpha 2b and interleukin-2 bolus infusion in metastatic renal cell carcinoma. Cancer 1993; 72: 1733–1742
   PubMed Web of Science ®Google Scholar
• Lim S. H., Worman C. P., Goldstone A. H. Lymphocyte activation in patients with acute myelocytic leukemia evidence for the presence of myeloblast antigen?. Cancer Immunol. Immunother. 1991b; 33: 417–420
   PubMed Web of Science ®Google Scholar
• Fierro T., Liao X. S., Lusso P., Bonferroni M., Matera L., Cesano A., Lista P., Arione R., Forni G., Foa R. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 1988; 2: 50–54
   PubMed Web of Science ®Google Scholar
• Soiffer R. J., Murray C., Cochran K., Cameron C., Wang E., Schow P. W., Daley J. F., Ritz J. Clinical and immunological effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517–526
   PubMed Web of Science ®Google Scholar
• Teichmann J. V., Ludwig W. D., Thiel E. Cytotoxicity of interleukin-2 induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor. Leuk. Res. 1992; 16: 287–298
   PubMed Web of Science ®Google Scholar
• Rosolen A., Nakanishi M., Poplack D. G., Cole D., Qui-Nones R., Reaman G., Trepel J. B., Cote J. D., Sausville E. A., Marti G. E., Jaffe E. S., Neckers L. M., Colamonicic O. R. Expression of interleukin-2 receptor B subunit in hematopoietic malignancies. Blood 1989; 73: 1968–1972
   PubMed Web of Science ®Google Scholar
• Foa R., Caretto P., Fierro M. T., Bonferroni M., Car-Dona S., Guarini A., Lista P., Pegoraro L., Mandelli F., Forni G., Gavosto F. Interleukin-2 does not promote the in vitro and in vivo proliferation and growth of human acute leukemia cells of myeloid and lymphoid origin. Br. J. Haematol. 1990; 75: 34–40
   PubMed Web of Science ®Google Scholar
• Hoshino S., Oshimi K., Tsudo M., Miyasaka M., Tera-Mura M., Masuda M., Motoji T., Mizoguchi H. Flow cytometric analysis of expression of interleukin-2 receptor B chain on various leukemic cells. Blood 1990; 76: 767–774
   PubMed Web of Science ®Google Scholar
• Bergmann L., Mitrou P. S., Hoelzer D. Interleukin-2 in the treatment of acute myelocytic leukemias. In vitro data and presentation of a clinical concept. Haematology and Blood Transfusion. Acute Leukemias Pharmacokinetics, W. Hiddemann. Springer Verlag, Heidelberg 1992; 601–607
   Google Scholar
• Weidmann E., Brieger J., Fenchel K., Hoelzer D., Bergmann L., Mitrou P. S. IL-2 receptor (IL-2R) alpha, beta, and gamma chains expressed on blasts of acute myelocytic leukemia may not be functional. Ann. Hematol. 1994; 68(Suppl. 1)A21
   PubMedGoogle Scholar
• Adler A., Albo V., Blatt J., Whiteside T. L., Herberman R. B. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission. Blood 1989; 74: 1690–1697
   PubMed Web of Science ®Google Scholar
• Archimbaud E., Bailly M., Doré J. F. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br. J. Haematol. 1991; 77: 328–334
   PubMed Web of Science ®Google Scholar
• Heslop H. E., Gottlieb D. J., Bianchi A. C. M., Meager A., Prentice H. G., Mehta A. B., Hoffbrand A. V., Brenner M. K. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 1989; 74: 1374–1380
   PubMed Web of Science ®Google Scholar
• Chiao J. W., Heil M., Arlin Z., Lutton J. D., Choi Y. S., Leung K. Suppression of lymphocyte activation and functions by a leukemia cell derived inhibitor. Proc. Nat. Acad. Sci. 1986; 83: 3432–3436
   PubMed Web of Science ®Google Scholar
• Foa R., Fierro M. T., Cesano A., Guarini A., Bonferroni M., Raspadori D., Miniero R., Lauria F., Gavosto F. Defective lymphokine activated killer cell generation and activity in acute leukemia patients with active disease. Blood 1991c; 78: 1041–1046
   PubMed Web of Science ®Google Scholar
• Lim S H., Worman C. P., Jewell A., Goldstone A H. Production of tumor-derived supressor factor in patients with acute myeloid leukemia. Leuk. Res. 1991a; 15: 263–268
   PubMed Web of Science ®Google Scholar
• Brieger J., Jahn B., Fenchel K., Appelhans H., Bergmann L., Mitrou P. S. Expression of transforming growth factor-/31 and interleukin-10 mRNA indicate im-munosupressive potential of AML blasts. Ann. Haematol. 1992; 65(Suppl. 40), Abstract
   Google Scholar
• Hines J. D., Oken M. M., Mazza J. J., Keller A. M., Streeter R. R., Glick J. H. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J. Clin. Oncol. 1984; 2: 545–549
   PubMed Web of Science ®Google Scholar
• Zittoun R., Bury J., Stryckmanns P., Lowenberg B., Pee-Termans M., Rozendaal K. Y., Haanen C., Kerkhofs M., Jehn U., Willemze R. Amsacrine with high-dose cytarabine in acute leukemias. Cancer Treat. Rep. 1985; 69: 1447–1448
   PubMedGoogle Scholar
• Capiizzi R. L., Davis R., Powell B., Cuttner J., Ellison R. R., Cooper M. R., Dillman R., Major W. B., Dupre E., McIntyre O. R. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed myelogenous leukemia—a cancer and leukemia group B study. J. Clin. Oncol. 1988; 6: 499–508
   PubMed Web of Science ®Google Scholar
• Amadori S., Meloni G., Petti M. C., Papa G., Miniero R., Mandelli F. Phase II trial of intermediate dose AraC with sequential mitoxantrone in acute myelogenous leukemia. Leukemia 1989; 3: 112–114
   PubMed Web of Science ®Google Scholar
• Weidmann E., Bergmann L., Stock J., Kirsten R., Mitrou P. S. Rapid cytokine release in cancer patients treated with interleukin-2. J. Immunother. 1992; 12: 123–131
   PubMed Web of Science ®Google Scholar
• Bergmann L., Weidmann E., Bungert B., Hechler P., Mitrou P. S. Influence of various cytokines on the induction of lymphocyte activated killer (LAK) cells. Natural Immunity and Cell Growth Regulation 1990; 9: 265–273
   PubMedGoogle Scholar
• Fenchel K., Bergmann L., Brieger J., Jahn B., Mitrou P. S. Modulation of adhesion molecules (CAM) on lymphocytes by IL-2 and expression of CAM on blasts in patients with AML (Abstract). Proc. Am. Assoc. Cancer Res. 1993; 34: 471
   Google Scholar
• Ganser A., Heil G., Kolbe K., Maschmeyer G., Fischer J. Th, Bergmann L., Mitrou P. S., Hei W., Heimpel H., Huber C., Hoelzer D. Aggressive chemotherapy combined with G-CSF and maintenance therapy with inter-leukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myelocytic leukemia-initial results. Ann. Hematol. 1993; 66: 123–126
   PubMed Web of Science ®Google Scholar